Literature DB >> 29954940

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.

Maria R Ambrosio1, Stefano Lazzi1, Giuseppe Lo Bello1, Raffaella Santi2, Leonardo Del Porro1, Maria M de Santi3, Raffaella Guazzo1, Lucia Mundo1, Luigi Rigacci4, Sofia Kovalchuck4, Noel Onyango5, Alberto Fabbri6, Emanuele Cencini6, Pier Luigi Zinzani7, Francesco Zaja8, Francesco Angrilli9, Caterina Stelitano10, Maria G Cabras11, Giuseppe Spataro12, Roshanak Bob13, Thomas Menter14,15, Massimo Granai1, Gabriele Cevenini1, Kikkeri N Naresh15, Harald Stein13, Elena Sabattini16, Lorenzo Leoncini17.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29954940      PMCID: PMC6312021          DOI: 10.3324/haematol.2018.195958

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Tina Marie Green; Ken H Young; Carlo Visco; Zijun Y Xu-Monette; Attilio Orazi; Ronald S Go; Ole Nielsen; Ole V Gadeberg; Torben Mourits-Andersen; Mikael Frederiksen; Lars Møller Pedersen; Michael Boe Møller
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries.

Authors:  Kikkeri N Naresh; Hazem A H Ibrahim; Stefano Lazzi; Patricia Rince; Monica Onorati; Maria R Ambrosio; Chrystèle Bilhou-Nabera; Furrat Amen; Alistair Reid; Michael Mawanda; Valeria Calbi; Martin Ogwang; Emily Rogena; Bessie Byakika; Shahin Sayed; Emma Moshi; Amos Mwakigonja; Martine Raphael; Ian Magrath; Lorenzo Leoncini
Journal:  Br J Haematol       Date:  2011-07-01       Impact factor: 6.998

3.  Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists.

Authors:  Amer Z Mahmoud; Tracy I George; David R Czuchlewski; Qian-Yun Zhang; Carla S Wilson; Cordelia E Sever; Alexei G Bakhirev; Dahua Zhang; Nichole L Steidler; Kaaren K Reichard; Huining Kang; Kathryn Foucar; Mohammad A Vasef
Journal:  Mod Pathol       Date:  2014-11-28       Impact factor: 7.842

Review 4.  High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.

Authors:  Allison Rosenthal; Anas Younes
Journal:  Blood Rev       Date:  2016-09-30       Impact factor: 8.250

5.  MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.

Authors:  Thomas Menter; Hanine Medani; Raida Ahmad; Rashpal Flora; Pritesh Trivedi; Alistair Reid; Kikkeri N Naresh
Journal:  Br J Haematol       Date:  2016-07-22       Impact factor: 6.998

6.  Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.

Authors:  Katsuhiro Miura; Hiromichi Takahashi; Masaru Nakagawa; Asami Izu; Masahiko Sugitani; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Yujin Kobayashi; Noriyoshi Iriyama; Sumiko Kobayashi; Satomi Kiso; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Leuk Lymphoma       Date:  2015-10-22

Review 7.  Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.

Authors:  German Ott; Andreas Rosenwald; Elias Campo
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

8.  Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Authors:  Alex F Herrera; Matthew Mei; Lawrence Low; Haesook T Kim; Gabriel K Griffin; Joo Y Song; Reid W Merryman; Victoria Bedell; Christine Pak; Heather Sun; Tanya Paris; Tracey Stiller; Jennifer R Brown; Lihua E Budde; Wing C Chan; Robert Chen; Matthew S Davids; Arnold S Freedman; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Joyce Murata-Collins; Auayporn P Nademanee; Joycelynne M Palmer; German A Pihan; Raju Pillai; Leslie Popplewell; Tanya Siddiqi; Aliyah R Sohani; Jasmine Zain; Steven T Rosen; Larry W Kwak; David M Weinstock; Stephen J Forman; Dennis D Weisenburger; Young Kim; Scott J Rodig; Amrita Krishnan; Philippe Armand
Journal:  J Clin Oncol       Date:  2016-10-24       Impact factor: 44.544

Review 9.  Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.

Authors:  Clémentine Sarkozy; Alexandra Traverse-Glehen; Bertrand Coiffier
Journal:  Lancet Oncol       Date:  2015-11       Impact factor: 41.316

10.  MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.

Authors:  Michael J Kluk; Caleb Ho; Hongbo Yu; Benjamin J Chen; Donna S Neuberg; Paola Dal Cin; Bruce A Woda; Geraldine S Pinkus; Scott J Rodig
Journal:  Am J Clin Pathol       Date:  2016-02-01       Impact factor: 2.493

View more
  5 in total

1.  Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.

Authors:  Fabienne Lucas; Kerry A Rogers; Bonnie K Harrington; Rosa Lapalombella; Alexander Pan; Lianbo Yu; Justin Breitbach; Ralf Bundschuh; Virginia M Goettl; Zachary A Hing; Parviz Kanga; Rose Mantel; Deepa Sampath; Lisa L Smith; Ronni Wasmuth; Danielle K White; Pearlly Yan; John C Byrd; Jennifer A Woyach
Journal:  Clin Cancer Res       Date:  2019-07-11       Impact factor: 12.531

2.  Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.

Authors:  Zijun Y Xu-Monette; Li Wei; Xiaosheng Fang; Qingyan Au; Harry Nunns; Hua You; Máté Nagy; Alexandar Tzankov; Feng Zhu; Carlo Visco; Govind Bhagat; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Fredrick B Hagemeister; Xiaoping Sun; Xin Han; Heounjeong Go; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Yong Li; Bing Xu; Maher Albitar; Ken H Young
Journal:  Clin Cancer Res       Date:  2022-03-01       Impact factor: 13.801

3.  Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases.

Authors:  Lucia Mundo; Maria Raffaella Ambrosio; Francesco Raimondi; Leonardo Del Porro; Raffaella Guazzo; Virginia Mancini; Massimo Granai; Bruno Jim Rocca; Cristina Lopez; Susanne Bens; Noel Onyango; Joshua Nyagol; Nicholas Abinya; Mohsen Navari; Isaac Ndede; Kirkita Patel; Pier Paolo Piccaluga; Roshanak Bob; Maria Margherita de Santi; Robert B Russell; Stefano Lazzi; Reiner Siebert; Harald Stein; Lorenzo Leoncini
Journal:  Blood Cancer J       Date:  2019-11-20       Impact factor: 11.037

4.  Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.

Authors:  Pekka Peroja; Mette Pedersen; Tuomo Mantere; Peter Nørgaard; Jenni Peltonen; Kirsi-Maria Haapasaari; Jan Böhm; Esa Jantunen; Taina Turpeenniemi-Hujanen; Katrin Rapakko; Peeter Karihtala; Ylermi Soini; Kaija Vasala; Outi Kuittinen
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

5.  A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit : A position paper from the Italian Group of Haematopathology (G.I.E.).

Authors:  Arianna Di Napoli; D Remotti; C Agostinelli; M R Ambrosio; S Ascani; A Carbone; F Facchetti; S Lazzi; L Leoncini; M Lucioni; D Novero; S Pileri; M Ponzoni; E Sabattini; C Tripodo; A Zamò; M Paulli; L Ruco
Journal:  Virchows Arch       Date:  2019-08-06       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.